1/24/2024 | BK | Market Commentary: Ahead DB, Dun & Bradstreet, Caesars, Merlin Entertainments, Tricor/Vistra, Novolex break
|
1/23/2024 | BK | Novolex finalizes $2.96 billion term loan at 99.75 OID
|
1/17/2024 | BK | Market Commentary: Parexel, Ryan, International SOS, MKS, Idemia, Conservice break; Imperial, 1-800 revised
|
1/17/2024 | BK | Novolex launches $2.96 billion term loan at SOFR plus 375 bps
|
4/8/2022 | BKCVDDEMIGPV | Market Commentary: Oldcastle on deck; secondary closes volatile week on soft footing; Earthstone Energy at a premium
|
4/1/2022 | BKCVDDEMIGPV | Market Commentary: In junk bonds, Talen in focus on potential bankruptcy filing; Novolex improves; Yum! weakens
|
3/31/2022 | BKCVDDEMIGPV | Market Commentary: Junk secondary closes volatile quarter quietly; Novolex, Churchill at a premium; Talen dives
|
3/30/2022 | BK | Market Commentary: Novolex term loan frees to trade atop OID; Solenis accelerates commitment deadline
|
3/30/2022 | BK | Novolex lifts term loan to $3 billion, revises OID to 97.5
|
3/29/2022 | BKCVDDEMIGPV | Market Commentary: Junk secondary rallies on cease-fire optimism; EQT upgraded; Nielson jumps on buyout
|
3/28/2022 | BKCVDDEMIGPV | Market Commentary: Presidio adds-on; Novolex on deck; Plantronics spikes on buyout; YUM! improves
|
3/21/2022 | BKDDHY | S&P gives Novolex, loans, notes B, notes CCC+
|
3/21/2022 | BK | Market Commentary: Forefront Dermatology tweaks loan commitment deadline; Novolex comes to market
|
3/21/2022 | BKDDHY | Moody’s rates Novolex loans B2, notes B2, Caa2
|
3/21/2022 | BK | Novolex launches $2.63 billion term loan at SOFR plus 425 bps
|